MXPA05007158A - Formulacion farmaceutica con un agente activo insoluble. - Google Patents

Formulacion farmaceutica con un agente activo insoluble.

Info

Publication number
MXPA05007158A
MXPA05007158A MXPA05007158A MXPA05007158A MXPA05007158A MX PA05007158 A MXPA05007158 A MX PA05007158A MX PA05007158 A MXPA05007158 A MX PA05007158A MX PA05007158 A MXPA05007158 A MX PA05007158A MX PA05007158 A MXPA05007158 A MX PA05007158A
Authority
MX
Mexico
Prior art keywords
active agent
pharmaceutical formulation
pulmonary administration
insoluble active
particulates
Prior art date
Application number
MXPA05007158A
Other languages
English (en)
Spanish (es)
Inventor
G Weers Jeffry
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32713146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05007158(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MXPA05007158A publication Critical patent/MXPA05007158A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MXPA05007158A 2002-12-31 2003-12-31 Formulacion farmaceutica con un agente activo insoluble. MXPA05007158A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43721002P 2002-12-31 2002-12-31
PCT/US2003/041703 WO2004060351A2 (en) 2002-12-31 2003-12-31 Pharmaceutical formulation with an insoluble active agent for pulmonary administration

Publications (1)

Publication Number Publication Date
MXPA05007158A true MXPA05007158A (es) 2005-09-21

Family

ID=32713146

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007158A MXPA05007158A (es) 2002-12-31 2003-12-31 Formulacion farmaceutica con un agente activo insoluble.

Country Status (18)

Country Link
US (1) US20040156792A1 (https=)
EP (1) EP1589947B2 (https=)
JP (1) JP2006513236A (https=)
KR (1) KR20050095838A (https=)
CN (1) CN1741789A (https=)
AU (1) AU2003300137A1 (https=)
BR (1) BR0317810A (https=)
CA (1) CA2511523C (https=)
EA (1) EA200501001A1 (https=)
ES (1) ES2589578T5 (https=)
HU (1) HUP0500846A3 (https=)
MX (1) MXPA05007158A (https=)
NO (1) NO20053076L (https=)
PL (1) PL378270A1 (https=)
PT (1) PT1589947T (https=)
TR (1) TR200502522T2 (https=)
WO (1) WO2004060351A2 (https=)
ZA (1) ZA200505155B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ES2525087T5 (es) 2000-05-10 2018-06-28 Novartis Ag Polvos basados en fosfolípidos para administración de fármacos
JP2005514393A (ja) * 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
MXPA05007156A (es) * 2002-12-31 2005-09-21 Nektar Therapeutics Formulacion farmaceuticas aerosolizable para terapia para infecciones fungicas.
CA2523475C (en) 2003-05-28 2013-02-05 Nektar Therapeutics Pharmaceutical formulation comprising a water-insoluble active agent
US8513204B2 (en) * 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
CA2623256A1 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Receptacles and kits, such as for dry powder packaging
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US20120128728A1 (en) * 2005-12-28 2012-05-24 Novartis Pharma Ag Compositions Comprising Amphotericin B
EP1986679B1 (en) * 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
DE102006053375A1 (de) * 2006-11-10 2008-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mischung von Pulvern
MY152789A (en) * 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
PL220269B1 (pl) 2008-04-21 2015-09-30 Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego
WO2009140587A1 (en) 2008-05-15 2009-11-19 Novartis Ag Pulmonary delivery of a fluoroquinolone
CA2835771C (en) 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2010111132A2 (en) 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
TR200904500A2 (tr) 2009-06-10 2009-10-21 Öner Levent Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
CN103228266B (zh) 2010-10-29 2017-11-14 健康科学西部大学 三元混合物制剂
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
KR20160142283A (ko) * 2014-02-03 2016-12-12 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 아연 프로토포르피린의 마이크로입자 전달용 제형물
WO2016067132A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
CN104587457B (zh) * 2015-01-13 2017-03-22 广东海大畜牧兽医研究院有限公司 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
MX2018007512A (es) * 2015-12-24 2018-09-17 Philip Morris Products Sa Capsula de particula de nicotina.
CN114847965A (zh) 2016-02-01 2022-08-05 英凯达治疗公司 电子监测联合吸入药理学疗法管理心律失常
CA3060702A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
MY200258A (en) * 2017-06-28 2023-12-17 Philip Morris Products Sa Container with particles for use with inhaler
ES3040411T3 (en) 2018-03-22 2025-10-30 Incarda Therapeutics Inc A novel method to slow ventricular rate
GB201817863D0 (en) 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
GB201817865D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
GB201817860D0 (en) 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolised formulation
KR102891439B1 (ko) 2019-08-01 2025-11-25 인카다 테라퓨틱스, 인크. 항부정맥 제제
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
KR20240164801A (ko) 2022-03-21 2024-11-20 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 암포테리신 b의 지질-코팅된 결정을 포함하는 이온 채널 보형 조성물
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US437210A (en) 1890-09-30 Electric street-car
SE408265B (sv) * 1975-12-12 1979-06-05 Draco Ab Anordning for koldioxiddriven endosaerosol, avsedd for inhalering
US4247066A (en) * 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
IT1116047B (it) * 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3634952A1 (de) * 1986-10-14 1988-04-21 Bayer Ag Imidazo-pyrrolo-pyridin-derivate
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
WO1993000951A1 (en) * 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
JP3388896B2 (ja) * 1994-08-08 2003-03-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
ES2237767T3 (es) * 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6077543A (en) * 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
CN1169520C (zh) * 1997-09-29 2004-10-06 耐科塔医药公司 多孔微粒及其使用方法
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6257233B1 (en) * 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
AU4602399A (en) † 1998-06-30 2000-01-24 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Prolonged release ophthalmic compositions containing a fluoroquinolone
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
ES2525087T5 (es) † 2000-05-10 2018-06-28 Novartis Ag Polvos basados en fosfolípidos para administración de fármacos
US6357490B1 (en) * 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
CA2432319A1 (en) * 2000-12-21 2002-07-18 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents

Also Published As

Publication number Publication date
HUP0500846A3 (en) 2008-10-28
AU2003300137A1 (en) 2004-07-29
PL378270A1 (pl) 2006-03-20
ES2589578T5 (es) 2019-07-23
ES2589578T3 (es) 2016-11-15
CA2511523C (en) 2013-10-15
NO20053076L (no) 2005-09-13
ZA200505155B (en) 2006-04-26
CA2511523A1 (en) 2004-07-22
NO20053076D0 (no) 2005-06-23
EA200501001A1 (ru) 2005-12-29
JP2006513236A (ja) 2006-04-20
BR0317810A (pt) 2005-11-29
CN1741789A (zh) 2006-03-01
WO2004060351A3 (en) 2004-09-30
KR20050095838A (ko) 2005-10-04
US20040156792A1 (en) 2004-08-12
EP1589947B1 (en) 2016-06-15
PT1589947T (pt) 2016-09-05
EP1589947B8 (en) 2016-08-24
WO2004060351A2 (en) 2004-07-22
TR200502522T2 (tr) 2005-09-21
EP1589947B2 (en) 2019-01-30
HUP0500846A2 (en) 2008-05-28
EP1589947A2 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
MXPA05007158A (es) Formulacion farmaceutica con un agente activo insoluble.
AU2001263228A1 (en) Rapidly disintegrating solid oral dosage form
AR043863A1 (es) Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
WO2005023176A3 (en) Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides
AR030862A1 (es) Formulaciones medicinales en aerosol
WO2008002568A3 (en) Active agent formulations, methods of making, and methods of use
WO2001085137A3 (en) Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001289079A1 (en) Pharmaceutical compositions for sustained drug delivery
WO2008019996A3 (en) Formulations of flibanserin and method for manufacturing the same
EP1131050B8 (fr) Formes galeniques a delitement rapide en bouche et leur procede de preparation
WO2003024396A3 (en) Dry powder medicament formulations
WO2002011711A3 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
NZ510563A (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
WO2003075977A3 (en) Agglomerated particles for aerosol drug delivery
MY144021A (en) Pharmaceutical delivery system
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
MXPA04001933A (es) Composicion farmaceutica que comprende lumiracoxib.
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
AP2001002084A0 (en) Orally administered controlled delivery system for once daily adminstration of ciprofloxacin
TNSN05048A1 (en) Inhalation compositions with high drug ratios
TW200420304A (en) Orally administrable pharmaceutical compositions and methods for preventing food-drug interaction
BRPI0821739B8 (pt) sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica e método de preparação de sistema de liberação de droga
WO2005123086A3 (en) Ziprasidone dosage form
GR20030100286A (el) Μορφηαφαρμακευτικησαδοσολογιασαπουαφερειαφιλικεσαπροσατηνακυησηαενδειξεις
JP2000044463A (ja) 速溶解性錠剤